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The emergence of drug resistance in microbial pathogens
provides a poignant example of an evolutionary process with a
profound impact on human health. Fungal drug resistance poses a
particular concern given the limited number of clinically useful
antifungal drugs and the growing population of immunocompro-
mised individuals vulnerable to life-threatening fungal disease [1].
The efficacy of most antifungal drugs is compromised either by
host toxicity, fungistatic rather than fungicidal activity, or by the
emergence of drug resistance. Recent studies have revealed that
compromising the function of the molecular chaperone Hsp90 can
render resistant pathogens more responsive to treatment and can
thwart the evolution of fungal drug resistance [2].
The Molecular Chaperone Hsp90 Regulates the
Stability and Function of Diverse Signal
Transducers and Modulates the Translation of
Genotype to Phenotype
By stabilizing key cellular regulators, Hsp90 can buffer the
expression of genetic variation such that it accumulates in a silent
state and is exposed when Hsp90 function is compromised, such as
by stress [3,4]. Reducing Hsp90 function reveals new traits in
organisms as diverse as flies and plants, with broad implications for
evolutionary processes. Cancer provides a poignant example of
how Hsp90 can influence somatic evolution on the cellular level.
Hsp90 stabilizes mutant oncogenic proteins that are prone to
misfolding, thereby enabling malignant transformation [5].
Compromising Hsp90 function can reverse oncogenic traits.
Hsp90 has yet another distinct role in fungal evolution: by
stabilizing unmutated regulators of cellular signaling, Hsp90
enables stress responses required for survival of drug exposure
and for the phenotypic consequences of diverse resistance
mutations.
Hsp90 Enables the Emergence and Maintenance
of Resistance to the Azole Antifungals in the
Model Yeast Saccharomyces cerevisiae and the
Leading Fungal Pathogen of Humans, Candida
albicans (Figure 1)
The azoles are the most widely deployed class of antifungals.
They exert fungistatic activity by inhibiting the biosynthesis of
ergosterol, the major sterol of fungal cell membranes. Specifically,
they inhibit the activity of lanosterol 14a-demethylase (Erg11) in
the ergosterol biosynthetic pathway and result in the accumulation
of a toxic sterol intermediate that results in cell membrane stress
[2]. Compromising Hsp90 blocks the rapid evolution of azole
resistance and abrogates resistance that was acquired by diverse
mutations [6]. In S. cerevisiae, Hsp90’s role in azole resistance
depends upon the underlying mechanism of resistance. Mecha-
nisms that allow the cell to cope with drug-induced stress, such as
loss of function of Erg3, which blocks the accumulation of the toxic
sterol that would otherwise accrue when the azoles inhibit Erg11,
are critically dependent upon Hsp90 function. Mechanisms that
bypass drug toxicity, such as overexpression of drug pumps that
efflux the drug from the cell, confer Hsp90-independent resistance.
Pharmacological inhibition of Hsp90 reduces resistance of C.
albicans clinical isolates that evolved resistance in a human host
and, importantly, converts the fungistatic azoles into a fungicidal
combination [6,7]. Febrile temperatures reached in humans
challenged by infections phenocopy Hsp90 inhibition, reducing
fungal drug resistance.
In C. albicans and One of the Most Lethal Moulds,
Aspergillus fumigatus, Hsp90 Governs Resistance to
the Only New Class of Antifungals to Reach the
Clinic in Decades, the Echinocandins (Figure 1)
The echinocandins exert fungistatic activity on many fungal
species by inhibiting synthesis of (1,3)-b-D-glucan, a critical
component of the fungal cell wall, resulting in cell wall stress [1,2].
Pharmacological or genetic impairment of Hsp90 function reduces
echinocandintoleranceofC.albicanslaboratorystrainsandresistance
of C. albicans clinical isolates and creates a fungicidal combination
[8]. Pharmacological inhibition of Hsp90 also enhances the activity
of echinocandins against A. fumigatus[7] and against the emerging
pathogen Aspergillus terreus[6]. Inhibition of Hsp90 enhances the
activity of an azole against A. fumigatus, though this effect is
contingent onthe environmentalconditions [7]. Relative to theyeast
species discussed above, little isknown about the roleof Hsp90 inthe
evolution of drug resistance in filamentous fungi.
Hsp90 Enables Resistance of Diverse Fungi to
Drugs Targeting the Cell Membrane and the Cell
Wall via the Client Protein Calcineurin (Figure 1)
Calcineurin is a protein phosphatase that regulates responses to
a myriad of stresses in fungal species [9], including a response to
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echinocandin-induced cell wall stress in both C. albicans and A.
fumigatus[6,8,10–12]. Hsp90 physically interacts with the catalytic
subunit of calcineurin, maintaining it in a stable conformation that
is poised for activation [8,13]. Compromising calcineurin function
phenocopies compromising Hsp90 function, reducing fungal drug
resistance [1,2,8,9]. In S. cerevisiae and C. albicans, a key effector of
the calcineurin-dependent response to azoles is the transcription
Figure 1. Hsp90’s role in fungal drug resistance. Compromising Hsp90 function enhances the activity of fungistatic antifungal drugs, creating
fungicidal drug combinations, and can block the evolution of drug resistance. Middle panel, left column indicates that in a wild-type fungal cell
(shown in yellow) Hsp90 stabilizes calcineurin, enabling calcineurin-dependent stress responses that are required to survive exposure to fungistatic
antifungal drugs (azoles and echinocandins for C. albicans and echinocandins for A. fumigatus). Middle panel, right column indicates that
compromising Hsp90 function abrogates calcineurin-dependent stress responses, rendering fungistatic agents fungicidal (dead fungal cell shown in
grey). Top panel, in S. cerevisiae, a rapid selection regime favors the emergence of Hsp90-dependent azole resistance (orange fungal cell with dashed
perimeter to indicate that resistance is contingent upon Hsp90-mediated stress responses). Bottom panel, in S. cerevisiae, a gradual selection regime
favors the emergence of Hsp90-independent resistance (orange fungal cell with solid perimeter).
doi:10.1371/journal.ppat.1000471.g001
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lated and translocates to the nucleus to activate a stress-responsive
transcriptional program [14]. Crz1 plays a partial role in azole
tolerance in both yeast species [15,16] and it also plays a partial
role in echinocandin tolerance in C. albicans[8], implicating the
involvement of other downstream effectors of calcineurin. In S.
cerevisiae, another downstream effector involved in azole resistance
is the integral membrane protein of the endoplasmic reticulum,
Hph1, which is dephosphorylated by calcineurin [15]. Since
Hsp90 interacts with many other client proteins [17], there may
well be many other stress response pathways through which Hsp90
influences drug resistance.
Hsp90 Provides a Powerful Therapeutic Target for
Diverse Fungal Diseases
Inhibiting Hsp90 can enhance the activity of existing antifun-
gals, rendering resistant pathogens more responsive to treatment,
and can also block the emergence of drug resistance, creating
fungicidal drug combinations. Notably, Hsp90 inhibitors are in
advanced phase clinical development as anticancer agents [5].
Combination therapy with Hsp90 inhibitors that are well tolerated
in humans and azoles rescues lethal C. albicans infections in a
tractable and well validated invertebrate host–model system, the
wax moth Galleria mellonella[7]. Importantly, the efficacies of
antifungal therapies in G. mellonella larvae correspond well with
efficacies in humans and fungal virulence in this model correlates
well with virulence in mammalian models of fungal disease [18].
Combination therapy with an Hsp90 inhibitor and an echino-
candin rescues larvae from lethal A. fumigatus infections [7].
Translation of this novel combination therapy strategy to a mouse
model of disseminated C. albicans infection is hampered by toxicity
associated with inhibiting host Hsp90 in the context of acute
fungal infection [7]. However, genetic compromise of C. albians
Hsp90 expression enhances the therapeutic efficacy of an azole
and an echinocandin in a mouse model of disseminated
candidiasis, providing genetic proof-of-principle for combination
therapy [7,8]. Further emphasizing the promise of targeting fungal
Hsp90, a recombinant antibody against C. albicans Hsp90
increased fungal clearance and reduced mortality in combination
with amphotericin B in a clinical study [19], though the
mechanism by which the antibody mediates these effects remains
enigmatic.
Hsp90 is poised to influence diverse facets of fungal biology as a
consequence of its function in regulating the activity of a myriad of
signal transducers. In C. albicans, Hsp90 governs cellular circuitry
required not only for drug resistance but also for a key
developmental transition from yeast to filamentous growth that
is required for virulence [20]. This morphogenetic transition is
normally regulated by environmental cues, such as exposure to
serum, coupled with elevated temperature that is required to
relieve Hsp90-mediated repression of the morphogenetic program.
Compromising Hsp90 induces a transition from yeast to
filamentous growth by activating Ras1-protein kinase A signaling.
Genetic depletion of C. albicans Hsp90 results in complete
clearance of an infection in a mouse model of disseminated
disease [20]. This is consistent with Hsp90’s essentiality and its role
in morphogenesis, given that morphogenetic flexibility is required
for virulence and that compromising Hsp90 drives filamentous
growth. Independent of the mechanism, this reinforces the
prospect for targeting Hsp90 in fungal pathogens as a powerful
therapeutic strategy. Hsp90 inhibitors may provide an even
broader therapeutic paradigm for infectious disease. Hsp90
inhibitors possess potent anti-malarial activity, thus extending
their spectrum of activity to the parasite Plasmodium falciparum[21].
With Hsp90’s capacity to sense temperature and orchestrate
cellular signaling that governs drug resistance and developmental
transitions, it provides an Achilles’ heel for diverse pathogens. The
challenge ahead lies in developing selective pharmacological
agents capable of distinguishing between Hsp90 chaperone
machineries of the pathogen and the host.
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